Christina Mattina

Participants exposed critical gaps in the diagnosis, treatment, and coordination of care for patients with heart failure with preserved ejection fraction and charted a path forward.

The 2026 EHA Congress, convening in Stockholm next week, will bring the global hematology community together for 4 days of science, debate, and discovery.

A thriving gut microbiome is associated with better clinical outcomes after CAR T-cell therapy for lymphoma and myeloma.

Longer patient survival times require a shift toward earlier surrogate end points, with measurable residual disease (MRD) providing robust evidence of its utility for accelerating access to myeloma treatment.

Final results of the CLL14 study reveal the efficacy of 1-year venetoclax-obinutuzumab therapy for chronic lymphocytic leukemia.

Experts sparred over the feasibility and appropriateness of using MRD to determine the duration of first-line treatment for CLL).

As research becomes more globalized, regulators, trial designers, and investigators across regions must communicate to ensure new drugs stand the best chance of becoming available to patients.

Phase 3 trials in CLL, AML, multiple myeloma, and myelofibrosis headlined the EHA 2026 late-breaking session, alongside early CAR T-cell data in B-cell lymphoma and immune thrombocytopenia.

Italian study finds most MS patients start biosimilars unaware, exposing education gaps and highlighting MS nurses as key to boosting trust and uptake.

EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.